Synonyms:physostigmine, Eserine, 57-47-6, Antilirium, Physostol, Esromiotin, (-)-physostigmine, Ezerin, Calabarine, Erserine, Fysostigmin, cogmine, (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate, eserin, Eserinum, Eserolein, methylcarbamate (ester), Eserine sulfate, CHEMBL94, NSC-30782, 9U1VM840SP, DTXSID3023471, CHEBI:27953, MCV-4484, NSC30782, NCGC00093889-03, [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-methylcarbamate, Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis), DTXCID603471, Fysostigmin [Czech], CHEMBL537674, Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-, (3aS,8aR)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-methylcarbamate, CAS-57-47-6, CCRIS 3422, HSDB 3161, MCV 4484, EINECS 200-332-8, Eserolein, methylcarbamate, NIH 10421, NSC 30782, Physostigmine [USP:BAN], RCRA waste no. P204, physostigmin, UNII-9U1VM840SP, CS 58525, Methyl-carbamic acid, ester with eseroline, Carbamic acid, methyl-, ester with eseroline, (-) physostigmine, Eserine (TN), Physostigmine (USP), Spectrum_000916, Spectrum_001789, ESERINUM [HPUS], SpecPlus_000381, Prestwick0_000566, Prestwick1_000566, Prestwick2_000566, Prestwick3_000566, Spectrum2_000330, Spectrum2_000757, Spectrum2_001283, Spectrum3_000545, Spectrum3_000901, Spectrum4_000997, Spectrum4_001631, Spectrum4_001913, Spectrum5_000441, Spectrum5_000626, Spectrum5_001672, PHYSOSTIGMINE [MI], physostigmine.salicylic acid, 1,2,3,3abeta,8abeta-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)-indol-5-yl methylcarbamate, PHYSOSTIGMINE [HSDB], Lopac0_000483, SCHEMBL24044, BSPBio_000352, BSPBio_002189, KBioGR_001433, KBioGR_002061, KBioGR_002533, KBioSS_001396, KBioSS_002279, PHYSOSTIGMINE [VANDF], (3aS-cis)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-ol methylcarbamate (ester), MLS001304022, DivK1c_006477, PHYSOSTIGMINE [MART.], SPECTRUM1500753, SPBio_000339, SPBio_000774, SPBio_001285, SPBio_002571, PHYSOSTIGMINE [WHO-DD], BPBio1_000388, cid_657348, GTPL6598, MEGxp0_001872, ACon1_000097, BDBM11023, KBio1_001421, KBio2_001396, KBio2_002278, KBio2_003964, KBio2_004846, KBio2_006532, KBio2_007414, KBio3_001689, KBio3_001842, Eserine, >=98.0% (N), HMS1921G06, HMS2089M11, HMS2236L08, HMS3261B07, BCP19735, Carbamic acid, ester with eseroline, HY-N6608, PHYSOSTIGMINE [USP IMPURITY], Tox21_111228, Tox21_301591, Tox21_500483, BDBM50004000, BDBM50222010, CCG-38605, MFCD00151090, AKOS016843649, Tox21_111228_1, DB00981, LP00483, SDCCGMLS-0066585.P001, SDCCGSBI-0050467.P005, NCGC00093889-01, NCGC00093889-02, NCGC00093889-04, NCGC00093889-05, NCGC00093889-06, NCGC00093889-07, NCGC00093889-08, NCGC00093889-09, NCGC00093889-10, NCGC00093889-12, NCGC00093889-13, NCGC00093889-20, NCGC00255345-01, NCGC00261168-01, AC-15983, Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)-, SMR000718753, SBI-0050467.P004, CS-0034353, EU-0100483, P0406, Physostigmine 100 microg/mL in Acetonitrile, C06535, D00196, E 8375, EN300-23839407, Q410595, Eserine; Antilirium; Physostol; Esromiotin; Ezerin, SR-01000075341-1, WLN: T B556 EN GNTT&J B1 E1 G1 KOVM1, BRD-K25650355-001-02-5, BRD-K25650355-059-02-3, BRD-K25650355-059-12-2, (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate hydrochloride, (3aS,8aR)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-methylcarbamate; 2-hydroxybenzoic acid, 1,2,3,3A.BETA.,8A.BETA.-HEXAHYDRO-1,3A,8-TRIMETHYLPYRROLO(2,3-B)-INDOL-5-YL METHYLCARBAMATE, Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, 5-(N-methylcarbamate), (3aS,8aR)-, Pyrrolo[2, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-
Pubchem:PUBCHEM:5983
Id:43caa6ec-678b-5ab4-a7c7-89c063ee1c15
Description:nan
